

Inpatient Quick Start (based on normal renal function, please verify using Cockcroft-Gault)

Infectious Disease Syndrome	Pathogens	First line treatment	Moderate-severe allergy	Duration
<b>Lung infections</b>				
Community Acquired Pneumonia (CAP) (Floor)	<i>Streptococcus pneumoniae</i> , <i>Mycoplasma pneumoniae</i> , <i>Chlamydia pneumoniae</i> <i>Haemophilus influenzae</i> , <i>Klebsiella pneumoniae</i>	Ceftriaxone 1g IV q24 + Doxycycline 100mg po BID	Levofloxacin 750mg po daily	5 days
CAP (ICU)	Same as floor plus Methicillin Resistant <i>Staphylococcus aureus</i> and Methicillin-sensitive <i>Staphylococcus aureus</i> (MRSA/MSSA)	Vancomycin per pharmacy Ceftriaxone 2g IV q24 Azithromycin 500mg po/IV daily	Linezolid 600mg po/IV BID Levofloxacin 750mg IV/po q24	5 days
Hospital Acquired Pneumonia or Bronchiectasis flare	<i>Pseudomonas</i> spp., other lactose negative GNR, plus above	Cefepime 2g IV q8 + Vancomycin per pharmacy (Meropenem can be used for critically ill patients in lieu of cefepime)	Levofloxacin 750mg IV/po daily Meropenem 1g IV q8 if critically ill + Vancomycin per pharmacy	5-7 days (can extend to 14d for CF)
Lung abscess	Oral anaerobes, staphylococci, streptococci	Ampicillin-sulbactam 3g IV q6; step down to Amoxicillin-clavulanate 875mg po BID	Levofloxacin 500mg po daily +metronidazole 500mg po daily	2-4 weeks
<b>Complicated intra-abdominal infections</b>				
Diverticulitis Perforated viscus	Enterobacteriales <i>Bacteroides</i> spp	Ceftriaxone 1g IV q24 plus metronidazole 500mg po/IV BID	Ciprofloxacin 500mg PO Q12 or 400mg IV Q12 + Metronidazole 500mg PO or IV Q8	4 days after source control 10-14 days if no source control
Septic shock from cIAI	Enterobacteriales <i>Bacteroides</i> spp	Piperacillin-tazobactam 3.375g IV Q8 extended infusion OR Meropenem 1g IV Q8 extended infusion if h/o ESBL	Vancomycin per pharmacy + Meropenem 1g IV Q8 extended infusion if no meropenem allergy*	Variable
<b>Urinary Tract Infections</b>				
Floor	Enterobacteriales	Ceftriaxone 1g IV q24  Ertapenem 1g IV q24 if prior history of ESBL, immunocompromised or renal transplant	Ciprofloxacin 500mg po Q12 or 400mg IV Q12	5 days if cystitis 7-10 days if pyelonephritis
ICU	Enterobacteriales	Meropenem 1g IV Q8 extended infusion	Meropenem 1g IV Q8 extended infusion unless true meropenem allergy*	7-10 days
<b>Skin and soft tissue infections</b>				
Floor	Group A streptococcus <i>Staphylococcus aureus</i>	Cefazolin 2g IV Q8	Vancomycin per pharmacy	7-10 days
ICU	Group A streptococcus <i>Staphylococcus aureus</i> <i>Vibrio</i> , <i>Aeromonas</i> , Clostridial species	Vancomycin per pharmacy + Ceftriaxone 2g IV Q24 + Clindamycin 900mg IV Q8  Linezolid 600mg IV/po BID can be used in lieu of vancomycin + clindamycin for both MRSA coverage and toxin inhibition for Group A Strep	Vancomycin per pharmacy  Add if c/f necrotizing infection: Meropenem 1g IV Q8 extended infusion if no meropenem allergy* + Clindamycin 900mg IV Q8 if c/f Group A Strep only (v Linezolid 600mg IV/po BID to replace both clinda and vancomycin)	Variable, depends on surgical management of necrotizing fasciitis

CNS infections				
Meningitis	<i>Streptococcus pneumoniae</i> <i>N. meningitidis</i> <i>Haemophilus influenzae</i>	Vancomycin per pharmacy + Ceftriaxone 2g IV Q12  Add: Ampicillin 2g IV Q4 if c/f <i>Listeria monocytogenes</i>  Acyclovir 10mg/kg (IBW) IV Q8 if c/f HSV/VZV with adequate hydration	Vancomycin per pharmacy + Meropenem 2g IV Q8 extended infusion if no allergy to meropenem  Add: Cotrimoxazole 5mg/kg IV Q8 if c/f <i>Listeria</i>  Acyclovir 10mg/kg (IBW) IV Q8 if c/f HSV/VZV	7 days <i>N. meningitidis</i> and <i>H influenzae</i> 14 days <i>Streptococcus pneumoniae</i> 14-21 days for HSV meningoencephalitis 14-21 days <i>Listeria monocytogenes</i>
Meningitis in the setting of VP shunt or recent neurosurgery	MRSA <i>Pseudomonas</i> spp., other lactose negative non-fermenters	Vancomycin per pharmacy + Cefepime 2g IV Q8 extended infusion	Vancomycin per pharmacy + Meropenem 2g IV Q8 extended infusion if no allergy to meropenem	variable
Neutropenic Fever				
Floor	MRSA if CLASBI  Viridans group streptococci β-hemolytic streptococci <i>Pseudomonas aeruginosa</i>	Vancomycin if concern for CLABSI, SSTI, known staphylococcal infection, hemodynamic instability  Piperacillin-tazobactam 4.5g IV Q8 extended infusion  Meropenem if history of ESBL, allogeneic HSCT, or hemodynamic instability	Vancomycin per pharmacy +  (Meropenem 1g IV Q8 extended infusion if no allergy to meropenem can be used in lieu of aztreonam + metronidazole)	Until afebrile for at least 48-72 hours
ICU	MRSA  Viridans group streptococci β-hemolytic streptococci <i>Pseudomonas aeruginosa</i>	Vancomycin per pharmacy  Meropenem 1g IV Q8 extended infusion	Vancomycin per pharmacy + Meropenem 1g IV Q8 extended infusion* + Tobramycin per pharmacy	Until afebrile for at least 48-72 hours
Sepsis of unknown origin				
No history of ESBL	unknown	Vancomycin per pharmacy + Piperacillin-tazobactam 3.375g IV Q8 extended infusion OR Cefepime 2g IV Q8 extended infusion	Vancomycin per pharmacy +  (Meropenem 1g IV Q8 extended infusion can be used in lieu of aztreonam and metronidazole if no allergy to meropenem)  + Tobramycin per pharmacy	Variable
History of ESBL	unknown	Vancomycin per pharmacy + Meropenem 1g IV Q8 extended infusion	Vancomycin per pharmacy +  Meropenem 1g IV Q8 extended infusion if no allergy* to meropenem  + Tobramycin per pharmacy	Variable

\*if concern for meropenem allergy, use aztreonam 2g IV q6-8 +/- metronidazole 500mg IV/po q8 for severe intraabdominal infections including typhlitis for neutropenic fever